search
Back to results

Pediatric Study to Access Pharmacokinetics and Safety of Oraqix Gel

Primary Purpose

Periodontal Disease

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
lidocaine and prilocaine
Sponsored by
Dentsply International
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Periodontal Disease

Eligibility Criteria

6 Years - 17 Years (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • 6 and 17 and eleven twelfths
  • requires tooth extraction
  • healthy having not taken any prescription or over the counter medications within 60 days of first visit
  • must be a minimum of 15 kg

Exclusion Criteria:

  • anesthesia required for treatment other than study material
  • given blood within 90 days of first visit
  • pregnant
  • allergic to local anesthetic
  • documented history of glucose-6-phosphate dehydrogenase deficiency
  • history of congenital idiopathic methemoglobinemia
  • does not have a loose tooth easily extracted or who, in the opinion of the Investigator, is not suitable for tooth extraction using only topical anesthetic

Sites / Locations

  • Virginia Commonweath School of Dentistry

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Oraqix for tooth extraction

Arm Description

Outcomes

Primary Outcome Measures

Pharmacokinetics
The study focused on the pharmacokinetics of prilocaine and lidocaine, o-toluidine (metabolite of prilocaine) and 2, 6-xylidine (metabolite of lidocaine). We evaluated blood samples of15 subjects at the following time points: pre-dose, at 5,10,15,30, 60, 90, 120 and 240 min post dose. We calculated Cmax (maximum observed plasma concentration) and Tmax (time to maximum plasma concentration).

Secondary Outcome Measures

Safety
The % MetHb levels and vital signs (pulse, systolic and diastolic pressure) were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose. ECG taken at pre-dose and 1, 2 and 4h post dose, measurement of heart rate and PR, QRS, QT and QTcB intervals. Visual analogue scale conducted at pre-dose (immediately before Oraqix administration), immed. post extraction, at 0.25, 0.5, 1 and 2h post dose and prior to discharge just after 4h post dose. For each subject, phone call was made at +24h as follow up pursuant to the protocol.
Vital Signs (Pulse)
Vital signs (pulse, systolic and diastolic pressure) were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.
Vital Signs (Systolic Pressure)
Vital Signs (Diastolic Pressure)
ECGs (Ventricular Heart Rate)
Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.
ECGs (PR Interval)
Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.
ECGs (QRS Duration)
Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.
ECGs (QT Interval)
Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.
ECGs (QTcB Interval)
Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.

Full Information

First Posted
June 24, 2011
Last Updated
July 21, 2020
Sponsor
Dentsply International
search

1. Study Identification

Unique Protocol Identification Number
NCT01591616
Brief Title
Pediatric Study to Access Pharmacokinetics and Safety of Oraqix Gel
Official Title
A Phase 4 Pediatric Study to Assess the Pharmacokinetics and Safety of Oraqix Gel in Healthy Children and Adolescent Volunteers Following Tooth Extraction
Study Type
Interventional

2. Study Status

Record Verification Date
July 2020
Overall Recruitment Status
Completed
Study Start Date
April 2010 (undefined)
Primary Completion Date
April 2012 (Actual)
Study Completion Date
April 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Dentsply International

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To establish Oraqix is safe when used on adolescent volunteers.
Detailed Description
This is a single-center, uncontrolled, open-label, single administration patient study. Male and female subjects aged 6 through 17 years of age in need of primary tooth extraction will be recruited from the Principal Investigator's database and may be supplemented by advertising. Subjects who withdraw from the study prematurely will be replaced. Subjects will undergo an initial screening visit at which eligibility will be determined. After completion of informed consent/assent a physical examination, vitals, 12-lead ECG, and dental examination will be conducted. A medical history will be documented and a blood sample will be collected for analysis of biochemistry, hematology and as appropriate, serum pregnancy assessment for females. Subjects will return to the office approximately 1 to 10 days after Visit 1 for Visit 2. At Visit 2, study treatment will be administered and PK blood samples will be collected for analysis, and monitored for safety parameters. Up to a total of five cartridges of Oraqix® will be administered to the oral cavity in the area of the tooth extraction, based on the body weight of the subject. No more than five cartridges will be dispensed, since this is the maximum dose for this agent. The final sample will be collected 4 hours after administration of study material. An abbreviated dental examination will be conducted, any adverse events (AEs) will be documented and the subject will be discharged from the clinic. All subjects will be contacted by telephone approximately 24 hours after administration of study treatment. Study personnel will enquire about the occurrence of any AEs that have occurred since leaving the office. If appropriate, further follow-up of AEs will be arranged. In the absence of any ongoing AEs requiring follow up the subject will be considered to have completed the study at the completion of the telephone call.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Periodontal Disease

7. Study Design

Primary Purpose
Other
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
16 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Oraqix for tooth extraction
Arm Type
Other
Intervention Type
Drug
Intervention Name(s)
lidocaine and prilocaine
Other Intervention Name(s)
Oraqix periodontal gel
Intervention Description
Appropriate dose of Oraqix based on weight will be given before tooth extraction
Primary Outcome Measure Information:
Title
Pharmacokinetics
Description
The study focused on the pharmacokinetics of prilocaine and lidocaine, o-toluidine (metabolite of prilocaine) and 2, 6-xylidine (metabolite of lidocaine). We evaluated blood samples of15 subjects at the following time points: pre-dose, at 5,10,15,30, 60, 90, 120 and 240 min post dose. We calculated Cmax (maximum observed plasma concentration) and Tmax (time to maximum plasma concentration).
Time Frame
5, 10, 15, 30, 60, 90, 120, and 240 minutes
Secondary Outcome Measure Information:
Title
Safety
Description
The % MetHb levels and vital signs (pulse, systolic and diastolic pressure) were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose. ECG taken at pre-dose and 1, 2 and 4h post dose, measurement of heart rate and PR, QRS, QT and QTcB intervals. Visual analogue scale conducted at pre-dose (immediately before Oraqix administration), immed. post extraction, at 0.25, 0.5, 1 and 2h post dose and prior to discharge just after 4h post dose. For each subject, phone call was made at +24h as follow up pursuant to the protocol.
Time Frame
blood draws pre-dose, 2 and 4 hours postdose
Title
Vital Signs (Pulse)
Description
Vital signs (pulse, systolic and diastolic pressure) were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.
Time Frame
Pre-dose and every 10 minute to 240 minutes post-dose.
Title
Vital Signs (Systolic Pressure)
Time Frame
Pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.
Title
Vital Signs (Diastolic Pressure)
Time Frame
Pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose
Title
ECGs (Ventricular Heart Rate)
Description
Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.
Time Frame
Pre-dose, 1 hour, 2 hour, 4 hour post-dose.
Title
ECGs (PR Interval)
Description
Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.
Time Frame
Pre-dose, 1 hour, 2 hour, 4 hour post-dose.
Title
ECGs (QRS Duration)
Description
Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.
Time Frame
Pre-dose, 1 hour, 2 hour, 4 hour post-dose.
Title
ECGs (QT Interval)
Description
Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.
Time Frame
Pre-dose, 1 hour, 2 hour, 4 hour post-dose.
Title
ECGs (QTcB Interval)
Description
Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.
Time Frame
Pre-dose, 1 hour, 2 hour, 4 hour post-dose.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: 6 and 17 and eleven twelfths requires tooth extraction healthy having not taken any prescription or over the counter medications within 60 days of first visit must be a minimum of 15 kg Exclusion Criteria: anesthesia required for treatment other than study material given blood within 90 days of first visit pregnant allergic to local anesthetic documented history of glucose-6-phosphate dehydrogenase deficiency history of congenital idiopathic methemoglobinemia does not have a loose tooth easily extracted or who, in the opinion of the Investigator, is not suitable for tooth extraction using only topical anesthetic
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tegwyn Brickhouse, D.D.S PhD
Organizational Affiliation
Virginia Commonweath School of Dentistry
Official's Role
Principal Investigator
Facility Information:
Facility Name
Virginia Commonweath School of Dentistry
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23298
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Pediatric Study to Access Pharmacokinetics and Safety of Oraqix Gel

We'll reach out to this number within 24 hrs